WebMar 15, 2024 · Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy while reducing side effects, announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor. RHEA-AI. WebAug-30-22 04:40PM. Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering. PR Newswire. Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle …

Why Shares of Shuttle Pharmaceuticals Jumped 160.4% This Week

WebShuttle Pharmaceuticals Holdings revenue from 2024 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. WebShuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also offers cancer treatments with surgery, radiation therapy, chemotherapy, and immunotherapy. The company was founded by Anatoly Dritschilo, Mira Jung, and Milton Brown on December 18, 2012 and ... bitsat moderation process

Shuttle Pharmaceuticals Holdings Revenue 2024-2024 SHPH

WebJan 20, 2024 · The most recently filed 13Fs Web2 days ago · Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of … WebShuttle Pharmaceuticals trimmed its IPO’s size to 1.23 million units, down from 1.25 million units, and raised the price to $8.125 ($8.13) per unit, according to an S-1/A filing dated Aug. 25, 2024. Just two days before – on Aug. 23, 2024 – the company added Valuable Capital as a joint book-runner and reworked its IPO to 1. datang sleepless city